Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 5/20 | 0.47 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.38 |
| ▸ | SIRT2 | Q8IXJ6 | 8/20 | 0.37 |
| ▸ | SIRT1 | Q96EB6 | 7/20 | 0.37 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.37 |
| ▸ | NPY4R | P50391 | 2/20 | 0.37 |
| ▸ | NPY1R | P25929 | 1/20 | 0.37 |
| ▸ | NPY2R | P49146 | 1/20 | 0.37 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.37 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23268956 | 1.00 | FAP (0.47) | FAPMAP1LC3BSIRT2SIRT1SIRT3 | |
| SCHEMBL18909001 | 1.00 | FAP (0.47) | FAPMAP1LC3BSIRT2SIRT1SIRT3 | |
| SCHEMBL18823197 | 1.00 | FAP (0.47) | FAPMAP1LC3BSIRT2SIRT1SIRT3 | |
| SCHEMBL24068331 | 1.00 | FAP (0.47) | FAPMAP1LC3BSIRT2SIRT1SIRT3 | |
| SCHEMBL18823198 | 1.00 | FAP (0.47) | FAPMAP1LC3BSIRT2SIRT1SIRT3 | |
| SCHEMBL19387405 | 0.99 | FAP (0.46) | FAPMAP1LC3BSIRT2SIRT1SIRT3 | |
| SCHEMBL18823482 | 0.99 | FAP (0.46) | FAPMAP1LC3BSIRT2SIRT1SIRT3 | |
| SCHEMBL19750495 | 0.99 | FAP (0.46) | FAPMAP1LC3BSIRT2SIRT1SIRT3 | |
| SCHEMBL20340686 | 0.98 | FAP (0.46) | FAPMAP1LC3BSIRT2SIRT1SIRT3 | |
| SCHEMBL26412946 | 0.95 | FAP (0.47) | FAPMAP1LC3BSIRT2SIRT1SIRT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11541126-B1 | Anti-ASGR1 antibody TLR8 agonist comprising conjugates and uses thereof | SILVERBACK THERAPEUTICS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-20200199247-A1 | ANTIBODY CONJUGATES OF IMMUNE-MODULATORY COMPOUNDS AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. | 2020-06-25 | — | — | US | disclosed |
| WO-2017214456-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC. (US) | 2017-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200199247-A1 | ANTIBODY CONJUGATES OF IMMUNE-MODULATORY COMPOUNDS AND USES THEREOF | LTK, TGFBR2, TNIK | FAP 1851/4885MAP1LC3B 422/4885SIRT2 1722/4885 |
| US-11541126-B1 | Anti-ASGR1 antibody TLR8 agonist comprising conjugates and uses thereof | ASGR1, TLR8, HAVCR2 | FAP 3829/4885MAP1LC3B 1500/4885SIRT2 2353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.